Literature DB >> 16474203

Generalization of NMDA-receptor antagonists to the discriminative stimulus effects of kappa-opioid receptor agonists U-50,488H, but not TRK-820 in rats.

Tomohisa Mori1, Mutsuko Nomura, Kazumi Yoshizawa, Hiroshi Nagase, Toshiko Sawaguchi, Minoru Narita, Tsutomu Suzuki.   

Abstract

Generalizations of NMDA-receptor antagonists to the discriminative stimulus effects of kappa-opioid receptor agonists in rats were examined. Phencyclidine, MK-801, and ketamine, non-competitive NMDA-receptor antagonists, generalized to the discriminative stimulus effects of U-50,488H, but not those of TRK-820, whereas (+/-)-3-(2-carbaxypiperazine-4-yl) propyl-1-phosphonic acid (CPP), a competitive NMDA-receptor antagonist, and ifenprodil, an NR1/NR2B NMDA-receptor antagonist, did not, suggesting that non-competitive NMDA-receptor antagonists possess U-50,488H-like discriminative stimulus effects in rats. Since U-50,488H and phencyclidine both induce aversive effects, our findings indicate that the cue of the discriminative stimulus effects of U-50,488H and non-competitive NMDA-receptor antagonists may be associated with their aversive effects.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16474203     DOI: 10.1254/jphs.scj05006x

Source DB:  PubMed          Journal:  J Pharmacol Sci        ISSN: 1347-8613            Impact factor:   3.337


  3 in total

Review 1.  The dynorphin/κ-opioid receptor system and its role in psychiatric disorders.

Authors:  H A Tejeda; T S Shippenberg; R Henriksson
Journal:  Cell Mol Life Sci       Date:  2011-10-16       Impact factor: 9.261

Review 2.  Endogenous opiates and behavior: 2006.

Authors:  Richard J Bodnar
Journal:  Peptides       Date:  2007-09-11       Impact factor: 3.750

3.  Role of kappa-opioid receptors in the effects of salvinorin A and ketamine on attention in rats.

Authors:  Christina L Nemeth; Tracie A Paine; Joseph E Rittiner; Cécile Béguin; F Ivy Carroll; Bryan L Roth; Bruce M Cohen; William A Carlezon
Journal:  Psychopharmacology (Berl)       Date:  2010-04-01       Impact factor: 4.530

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.